Damora Therapeutics, Inc. Ordinary Shares
DMRA
27 hedge funds and large institutions have $25.7M invested in Damora Therapeutics, Inc. Ordinary Shares in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
2,343% more call options, than puts
Call options by funds: $171K | Put options by funds: $7K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
44% more capital invested
Capital invested by funds: $17.8M → $25.7M (+$7.88M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
4% more funds holding
Funds holding: 26 → 27 (+1)
0.19% more ownership
Funds ownership: 1.4% → 1.59% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.18M |
| 2 |
BlackRock
New York
|
+$559K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$185K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$174K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$559K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$22.2K |
| 3 |
Two Sigma Advisers
New York
|
-$10.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$9.04K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $5.18K | -$3.27K | -60 | -42% |
|
27
JP Morgan Chase
New York
| $2.15K | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| – | -$4.94K | -99 | Closed |
|
29
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2.79K | -56 | Closed |
|
DMRA Hedge Fund Activity: Q2 2023 in Review
27 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q2 2023, worth a combined $25.7M — up 44% from $17.8M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DMRA positions and 2 closed out — a net gain of 1 holder — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $2.18M. The largest seller was OrbiMed, cutting an estimated $559K.
- 27 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q2 2023, up from 26 in Q1 2023.
- Funds reported $25.7M of Damora Therapeutics, Inc. Ordinary Shares stock for Q2 2023, up 44% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q2 2023 and 2 closed out, a net change of +1 holder.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q2 2023 was Soleus Capital Management, an estimated $2.18M added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q2 2023 was OrbiMed, an estimated $559K sold.
Based on aggregated 13F filings for Q2 2023.